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Abstract: Endometrial cancer has a high prevalence among post-menopausal women in developed
countries. We aimed to explore whether certain metabolic patterns could be related to the characteristics
of aggressive disease and poorer survival among endometrial cancer patients in Western Norway.
Patients with endometrial cancer with short survival (n = 20) were matched according to FIGO
(International Federation of Gynecology and Obstetrics, 2009 criteria) stage, histology, and grade,
with patients with long survival (n = 20). Plasma metabolites were measured on a multiplex system
including 183 metabolites, which were subsequently determined using liquid chromatography-mass
spectrometry. Partial least square discriminant analysis, together with hierarchical clustering, was used
to identify patterns which distinguished short from long survival. A proposed signature of metabolites
related to survival was suggested, and a multivariate receiver operating characteristic (ROC) analysis
yielded an area under the curve (AUC) of 0.820–0.965 (p ≤ 0.001). Methionine sulfoxide seems to
be particularly strongly associated with poor survival rates in these patients. In a subgroup with
preoperative contrast-enhanced computed tomography data, selected metabolites correlated with
the estimated abdominal fat distribution parameters. Metabolic signatures may predict prognosis
and be promising supplements when evaluating phenotypes and exploring metabolic pathways
related to the progression of endometrial cancer. In the future, this may serve as a useful tool in
cancer management.
Keywords: metabolomics; biomarker; endometrial cancer
1. Introduction
Endometrial cancer (EC) is one of the most prevalent cancers among women in Western countries,
typically occurring after menopause, and having an increased incidence with advancing age, overweight
and obesity [1,2]. This type of gynecological malignancy most frequently presents as endometrioid
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carcinoma, which usually has a good prognosis when diagnosed at an early stage. Non-endometrioid
EC includes high-grade variants, like serous and clear-cell carcinomas, and often has a poorer prognosis.
In general, cancer cells have impaired energy metabolism, and metabolic intermediates typically
accumulate in tumors [3]. A deregulated uptake of glucose and amino acids, as well as a utilization of
intermediates from glycolysis and the tricarboxylic acid (TCA) cycle, have been considered as major
contributors to tumorigenesis [4]. Whereas an altered glucose metabolism is a well-recognized feature
of cancer cells, shifts involving fatty acid (FA) metabolism have more recently come into focus and,
more specifically, as opposed to in healthy cells, de novo FA synthesis frequently occurs in cancer
cells [3].
For patients with EC, there is an urgent need for biomarkers that can help predict the prognosis and,
hence, the necessary surgical procedure and personalize the post-surgical care. Currently, only classic
histologic classification is used for this purpose, with the aid of some molecular markers, which are,
however, used with little consensus among professionals [2]. Due to the association of EC with the
metabolic imbalances induced by, e.g., diabetes and obesity, it is likely to assume that metabolic features
may be associated with patient prognosis. We have previously demonstrated an association between a
high visceral fat percentage and the reduced survival of patients with EC [5]. In addition, as we have
shown already for blood steroids [6], plasma metabolites may also be associated with survival and could
serve as biomarkers for better prognostication. Metabolomics, the study of metabolites in body fluids
and tissues, is a promising tool which has now become more readily available, and has the advantage
that it only requires fluids like blood and urine which are easily and non- or minimally-invasively
collectable [7]. The aim of the current study was to identify metabolic patterns associated with survival
in a selected cohort of women diagnosed with EC. In addition, we aimed to explore whether specific
metabolic patterns were associated with the distribution of abdominal fat.
2. Results
2.1. Cohort Characteristics
The current study included 40 patients with EC, with a median (25th, 75th percentile) age of 72.0
(61.0, 78.5) years and a BMI of 24.0 (23.0, 27.0) kg/m2 (Table 1). Overall, patients were followed for
median 36.0 (16.5, 66.0) months. Patients with short survival developed recurrent EC during median
(25th, 75th percentile) 9.5 (3.50, 14.5) months and died after 16.5 (8.5, 27.0) months, whereas those
with long survival were alive and well while being followed for 66.0 (30.0, 70.5) months. There was a
significantly higher proportion with myometrial infiltration (>50%) among those with short survival,
compared with those having long survival (p = 0.03). A total of 15 patients had an endometrioid type
of EC, whereas 25 had non-endometrioid type.
2.2. Metabolites Associate with Survival
To explore whether blood metabolites or metabolite signatures are associated with patient survival,
we performed metabolomics analyses in blood samples collected from a cohort of 40 patients with EC,
20 of whom had long survival, whereas the other 20 had short survival.
The levels of over 180 different molecules including amino acids, biogenic amines, acylcarnitines,
hexoses, glycerophospholipids, and sphingolipids were quantified.
Partial least squares discriminant analysis (PLS-DA) was used to detect metabolites which
best distinguished cases in relation to survival, and EC patients with short survival could be well
distinguished from those with long survival (Figure 1a). The nine most important metabolites which
discriminated patients according to survival and having variable importance in projection (VIP) scores
>2.0 for component 1 are shown in the VIP heat map (Figure 1b). Results from the cross-validation and
permutation are shown in Figure S1 in the Supplementary Materials.
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Table 1. Clinico-pathological characteristics of included patients.




(n = 20) p
†
Age (years) 72.0 (61.0, 78.5) 67.0 (56.0, 77.0) 75.0 (63.5, 81.5) 0.10
Body Mass Index (BMI, kg/m2) 24.0 (23.0, 27.0) 24.0 (22.0, 26.5) 26.0 (23.0, 27.0) 0.20
Recurrence Free Survival (months) 28.5 (9.5, 66.0) 66.0 (60.0, 70.5) 9.5 (3.50, 14.5) <0.001
Recurrence, n (%) 21 (52.5) 1 (5.0) 20 (100) <0.001
Follow-up Time (months) 36.0 (16.5, 66.0) 66.0 (60.0, 70.5) 16.5 (8.5, 27.0) <0.001
Myometrial Infiltration ≥50%, n (%) 19 (47.5) 6 (30.0) 13 (65.0) 0.03
Histologic Type, n (%)
Endometrioid Type 15 (37.5) 7 (35.0) 8 (40.0) 0.74
Non-endometrioid Type
Clear Cell 3 (7.5) 3 (15.0) 0 (0) 0.07
Serous Papillary 8 (20.0) 3 (15.0) 5 (25.0) 0.43
Carcinosarcoma 11 (27.5) 6 (30.0) 5 (25.0) 0.72
Other non-endometrioid 3 (7.5) 1 (5.0) 2 (10.0) 0.55
Histologic Grade, n (%) #
Grade 1 6 (15.0) 3 (15.0) 3 (15.0) 1.00
Grade 2 4 (10.0) 2 (10.0) 2 (10.0) 1.00
Grade 3 5 (12.5) 2 (10.0) 3 (15.0) 1.00
FIGO Stage, n (%)
Stage I 36 (90.0) 18 (90.0) 18 (90.0) 1.00
Stage II 4 (10.0) 2 (10.0) 2 (10.0) 1.00
Values are presented as medians (25th, 75th percentiles) or counts (percentages), † Calculated by using the
Mann–Whitney U test for continuous variables and Chi-square for independence on binary variables, # Shown for
endometrioid cases only.Metabolites 2019, 9, x 4 of 16 
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Figure 1. PLS-DA and variable importance in projection (VIP) scores in survival analysis. Partial least 
square discriminant analysis (PLS-DA) was used to identify metabolites which could separate cases 
according to short (red) vs. long (green) survival (a); VIP heat map, showing metabolites with VIP 
scores >2.0 (based on component 1) (b). Abbreviations: C4:1, butenylcarnitine; Met SO, methionine 
sulfoxide. 
Next, a hierarchical clustering using the Euclidean distance measure and the Ward algorithm 
was performed, and 50 features were selected for the sake of visualization (Figure 2). The clustering 
separated the cohort into two main clusters, with 15 and 25 cases, respectively, but no obvious pattern 
was demonstrated in relation to survival. Furthermore, there was no significant difference in age or 
histological type between these clusters, but the fraction of patients with histologic grade 1 was 
higher in the largest cluster, compared to the smallest (p = 0.04). 
2.3. Metabolite Signature Modeling 
With the aim to propose a signature of metabolites that may identify patients with poor 
prognoses, the following three selection criteria were applied for the inclusion of metabolites based 
on differences between short and long survival: (1) metabolites with a statistically significant p value 
(<0.05) according to the Mann–Whitney U test; (2) Metabolites with a fold change >2; and/or (3) 
Metabolites with a VIP score >2.0 based on the PLS-DA. 
For further analyses, metabolites with a VIP score >2.0 for components 1 throughout 5 were 
included in Model 1; metabolites with a VIP score >2.0 for component 1 (but not throughout the other 
components 2–5) were included in Model 2, together with metabolites from Model 1; and metabolites 
with a VIP score >2.0 in one or more of components 2–5 (but < 2.0 for component 1) were included in 
Model 3, together with metabolites from model 1 and 2. 
Figure 1. PLS-DA and vari ble importance in projection (VIP) scores in survival analysis. Partial least
square discriminant analysis (PLS-DA) was u ed to identify metabolites whic ould separate cases
according to sh rt (red) vs. long (green) survival (a); VIP heat map, showing metabolites with VIP scores
> 2.0 (ba ed on component 1) (b). Abbreviations: C4:1, butenylcarnitin ; Met SO, methionine sulfoxide.
Next, a hierarchical clustering using the Euclidean distance measure and the Ward algorithm
was performed, and 50 fe tures were selected for the sake of visualization (Figure 2). The clustering
separated the cohort into two main clusters, with 15 and 25 cases, respectively, but no obvious pattern
wa demonstrated in rela ion t survival. Furthermore, there wa no significant difference in age or
histological type between these clusters, but the fraction of patients with histologic grade 1 was higher
in the largest cluster, compared to the smallest (p = 0.04).
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2.3. Metabolite Signature Modeling
With the aim to propose a signature of metabolites that may identify patients with poor prognoses,
the following three selection criteria were applied for the inclusion of metabolites based on differences
between short and long survival: (1) metabolites with a statistically significant p value (<0.05) according
to the Mann–Whitney U test; (2) Metabolites with a fold change >2; and/or (3) Metabolites with a VIP
score >2.0 based on the PLS-DA.
For further analyses, metabolites with a VIP score >2.0 for components 1 throughout 5 were
included in Model 1; metabolites with a VIP score >2.0 for component 1 (but not throughout the other
components 2–5) were included in Model 2, together with metabolites from Model 1; and metabolites
with a VIP score >2.0 in one or more of components 2–5 (but <2.0 for component 1) were included in
Model 3, together with metabolites from model 1 and 2.Metabolites 2019, 9, x 5 of 16 
 
 
Figure 2. Heatmap of the top metabolites differentially presented in patients with short and long 
survival. The heatmap illustrates the most relevant metabolites ranked by t-test according to short 
(red) and long (green) survival as defined on top. Histologic type is indicated below the survival 
(endometrioid, light grey; non-endometrioid, dark grey). Metabolites are clustered along the vertical 
axis, whereas subjects are clustered along the horizontal axis (main clusters are indicated on top). 
Levels of methionine sulfoxide (Met SO, p = 0.01) and hydroxypropionylcarnitine (C3-OH, p = 
0.04) significantly differed according to survival as assessed by the Mann–Whitney U test. None of 
the metabolites had a fold change >2 and, in addition, C3-OH was slightly under the detection limit 
(LOD, defined as the value below which metabolite quantification bears some level of uncertainty). 
Met SO was classified according to the VIP score, and was the only metabolite which fulfilled more 
than one criterium for the signature. Altogether, the selection criteria resulted in six metabolites in 
Model 1, ten metabolites in Model 2, and a total of 14 metabolites in Model 3 (listed in Table 2), which 
we propose as signatures for survival lengths among patients in the current study. 
  
Figure 2. Heatmap of the top metabolites differentially presented in patients with short and long
survival. The heatmap illustrates the most relevant metabolites ranked by t-test according to short
(red) and long (green) survival as defined on top. Histologic type is indicated below the survival
(endometrioid, light grey; non-endometrioid, dark grey). Metabolites are clustered along the vertical
axis, whereas subjects are clustered along the horizontal axis (main clusters are indicated on top).
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Levels of methionine sulfoxide (Met SO, p = 0.01) and hydroxypropionylcarnitine (C3-OH, p = 0.04)
significantly differed according to survival as assessed by the Mann–Whitney U test. None of the
metabolites had a fold change >2 and, in addition, C3-OH was slightly under the detection limit (LOD,
defined as the value below which metabolite quantification bears some level of uncertainty). Met SO
was classified according to the VIP score, and was the only metabolite which fulfilled more than one
criterium for the signature. Altogether, the selection criteria resulted in six metabolites in Model 1,
ten metabolites in Model 2, and a total of 14 metabolites in Model 3 (listed in Table 2), which we
propose as signatures for survival lengths among patients in the current study.
Table 2. Plasma metabolites associated with survival among 40 patients with endometrial cancer.




(n = 20) p
† VIP Score #
Amino Acids and Biogenic Amines (µM)
Asp 3 7.1 (5.9, 8.5) 6.8 (6.1, 7.9) 7.6 (5.8, 9.1) 0.76 5.32
ADMA 3 0.55 (0.30, 0.70) 0.50 (0.30, 0.80) 0.60 (0.30, 0.65) 0.90 2.93
Met SO 1 1.20 (1.00, 1.50) 1.05 (0.90, 1.25) 1.40 (1.10, 1.55) 0.01 5.43
Serotonin 1 0.75 (0.45, 1.25) 0.65 (0.45, 1.35) 0.90 (0.45, 1.25) 0.78 2.67
Spermidine 2 0.30 (0.30, 0.40) 0.30 (0.20, 0.40) 0.40 (0.30, 0.40) 0.17 2.08
Spermine 1** 0.20 (0.20, 0.30) 0.20 (0.20, 0.30) 0.20 (0.20, 0.30) 0.62 2.79
Acylcarnitines (µM)
C3-OH 1** 0.027 (0.023, 0.030) 0.026 (0.023, 0.028) 0.028 (0.025, 0.034) 0.04 1.63
C4:1 2** 0.023 (0.018, 0.026) 0.022 (0.017, 0.025) 0.023 (0.020, 0.027) 0.22 2.23
Sugar (µM)
Hexose H1 3 4051 (2915, 4868) 3776 (2915, 4714) 4098 (3014, 5385) 0.75 2.62
Glycerophospholipids and Sphingolipids (µM)
lysoPC-a-C18:2 2 27.0 (21.5, 35.6) 32.1 (22.3, 36.0) 25.3 (18.7, 35.3) 0.29 2.01
lysoPC-a-C24:0 2 0.38 (0.20, 0.54) 0.42 (0.20, 0.59) 0.36 (0.20, 0.52) 0.33 2.11
PC-aa-C36:5 1 39.4 (27.7, 56.9) 42.7 (38.2, 57.0) 30.2 (24.4, 55.0) 0.07 2.95
PC-ae-C30:1 3 0.026 (0.00, 0.12) 0.025 (0.00, 0.098) 0.026 (0.00, 0.15) 0.69 2.16
SM-C20:2 1 0.59 (0.43, 0.69) 0.57 (0.33, 0.65) 0.60 (0.47, 0.77) 0.16 3.07
Values are presented as medians (25th, 75th percentiles), † Calculated by using the Mann–Whitney U test;
# The highest VIP score based on components 1–5; 1 Model 1: methionine sulfoxide (Met SO, HMDB02005),
serotonin (HMDB00259), spermine (HMDB01256), hydroxypropionylcarnitine (C3-OH, HMDB13125), PC-aa-C36:5
(HMDB07890), and SM-C20:2 (HMDB13465); 2 Model 2: all metabolites in Model 1, spermidine (HMDB01257),
butenylcarnitine (C4:1, HMDB13126), lysoPC-a-C18:2 (HMDB10386), and lysoPC-a-C24:0 (HMDB10405); 3 Model
3: all metabolites in Model 1 and 2, aspartic acid (Asp, HMDB00191), asymmetric dimethylarginine (ADMA,
HMDB01539), hexose H1 (HMDB00143), and PC-ae-C30:1 (HMDB13402); HMDB names are given according to the
The Human Metabolome Database: http://www.hmdb.ca/metabolites. ** Those metabolites marked with double
asterisks had values that fell under the detection limits, therefore, though they could be measured, the prediction
may not be accurate.
2.4. Receiver Operating Characteristics Analyses
Area under the curves (AUCs) were calculated based on receiver operating characteristics (ROC)
curves as a measure of model discrimination. When studying the separate metabolites of the proposed
metabolic signature according to survival, the AUC was 0.729 (95% CIs 0.564–0.894) for Met SO
(p = 0.01) and 0.692 (95% CIs 0.525–0.860) for C3-OH (p = 0.04). Multivariate ROC analyses containing
metabolites of the proposed signature (Models 1–3) yielded an AUC between 0.820 and 0.965 (p ≤ 0.001)
(Figure 3a–c).
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Figure 3. Receiver operating characteristics (ROC) curves under three modeling methods. 
Multivariate ROC analyses based on the metabolites in Models 1–3, according to survival. Model 1 is 
based on the metabolites methionine sulfoxide (Met SO), serotonin, spermine, 
hydroxypropionylcarnitine (C3-OH), PC-aa-C36:5, and SM-C20:2 (AUC 0.820, 95% CIs 0.692–0.948) 
(a). Model 2 is based on all metabolites in Model 1, as well as spermidine, butenylcarnitine (C4:1), 
lysoPC-a-C18:2, and lysoPC-a-C24:0 (AUC 0.935, 95% CIs 0.865–1.000) (b). Model 3 is based on all 
metabolites in Models 1 and 2, as well as aspartic acid (Asp), asymmetric dimethylarginine (ADMA), 
hexose H1, and PC-ae-C30:1 (AUC 0.965, 95% CIs 0.913–1.000) (c). p values are based on the 
asymptotic 2-tail significance. 
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To identify pathways which may be differently affected in patients with short, compared to long 
survival, we performed a joint pathway analysis including transcriptomics data using 
MetaboAnalyst 4.0 [8]. A significance analysis of microarrays (SAM) was performed on tumor RNA 
across survival groups in the current patient cohort. All genes which had a fold change >2.0 (n = 96), 
as well as all 14 metabolites which were identified as potentially associated with survival with their 
corresponding fold changes were included in the analysis. The most affected statistically significant 
associated pathways were “Mucin type O-Glycan biosynthesis” (p = 0.008) and “Retinol metabolism” 
(p = 0.02). These two pathways were also among those showing the strongest pathway topology, in 
addition to “Linoleic acid metabolism”, “Taurine and hypotaurine metabolism”, and “Cyanoamino 
metabolism”. 
2.6. Metabolites Associated with Abdominal Fat Distribution 
While body mass index (BMI; kg/m2) is a frequently used measure to assess body fat, it is clear 
that the exact distribution of fat may also affect metabolic pathways in the body [9]. Fat is mainly 
stored either subcutaneously or viscerally, and can be estimated from computed tomography (CT) 
images. Previous work by our group has demonstrated the association between a high visceral 
abdominal fat volume (VAV) percentage and adverse outcomes in patients with EC [5]. The 
distribution of abdominal fat was measured by CT in a subgroup (n = 22) based on the current cohort, 
and estimates of long and short survival are shown in Table 3. None of the measurements for total 
abdominal fat volume (TAV, cm3), VAV (cm3), subcutaneous abdominal fat volume (SAV, cm3), VAV 
percentage, or waist circumference significantly differed between groups with short vs. long survival. 
  
Figure 3. Receiver operating characteristics (ROC) curves under three modeling methods. Multivariate
ROC analyses based on the metabolites in Models 1–3, according to survival. Model 1 is based on the
metabolites methionine sulfoxide (Met SO), serotonin, spermine, hydroxypropionylcarnitine (C3-OH),
PC-aa-C36:5, and SM-C20:2 (AUC 0.820, 95% CIs 0.692–0.948) (A). Model 2 is based on all metabolites
in Model 1, as well as spermidine, butenylcarnitine (C4:1), lysoPC-a-C18:2, and lysoPC-a-C24:0 (AUC
0.935, 95% CIs 0.865–1.000) (B). Model 3 is based on all metabolites in Models 1 and 2, as well as aspartic
acid (Asp), asymmetric dimethylarginine (ADMA), hexose H1, and PC-ae-C30:1 (AUC 0.965, 95% CIs
0.913–1.000) (C). p values are based on the asymptotic 2-tail significance.
2.5. Pathways Involved
To identify pathways which may be differently affected in patients with short, compared to long
survival, we performed a joint pathway analysis including transcriptomics data using MetaboAnalyst
4.0 [8]. A significance analysis of microarrays (SAM) was performed on tumor RNA across survival
groups in the current patient cohort. All genes which had a fold change >2.0 (n = 96), as well as all 14
metabolites which were identified as potentially associated with survival with their corresponding fold
changes were included in the analysis. The most affected statistically significant associated pathways
were “Mucin type O-Glycan biosynthesis” (p = 0.008) and “Retinol metabolism” (p = 0.02). Thes two
pathways were also among those showing the strongest pathway topology, in addition to “Linoleic
cid metabolism”, “Tau ine and hypotaurine metabolism”, and “Cyanoamino metabolism”.
2.6. Metabolites Associated with Abdominal Fat Distribution
While body mass index (BMI; kg/m2) is a frequently used measure to assess body fat, it is clear that
the exact distribution of fat may also affect metabolic pathways in the body [9]. Fat is mainly stored
either subcutaneously or viscerally, and can be estimated from computed tomography (CT) images.
Previous work by our group has demonstrated the association betwe n a high visceral abdomin l fat
volum (VAV) percentage and dverse outcomes in p tients with EC [5]. The distribution of abdominal
fat was measured by CT in a subgroup (n = 22) bas d on th cu rent cohor , and estimates of long
and short survival are shown in Table 3. None f the measurements f r total abdominal fat volume
(TAV, cm3), VAV (c 3), subcutaneous bdomin l fat volume (SAV, cm3), VAV percentage, or waist
circumfere ce significantly differed between groups with short vs. long survival.
Metabolites 2019, 9, 302 7 of 15
Table 3. Abdominal fat estimates from pre-operative computed tomography according to survival
among 22 patients with endometrial cancer.




(n = 12) p
†
TAV (cm3) 6933 (5654, 8746) 7131 (6534, 8746) 6758 (5373, 8683) 0.64
VAV (cm3) 2388 (1920, 3916) 2666 (2086, 3461) 2219 (1905, 3919) 0.74
SAV (cm3) 4151 (3329, 5389) 4437 (3916, 5923) 3980 (3263, 5252) 0.55
VAV% 37.4 (33.4, 43.5) 37.1 (31.3, 40.3) 38.0 (35.0, 45.7) 0.45
Waist Circumference (cm) 93.2 (86.2, 99.1) 91.6 (86.0, 95.9) 97.3 (87.0, 99.2) 0.34
Values are presented as medians (25th, 75th percentiles). † Calculated by using the Mann–Whitney U test.
Abbreviations: SAV: subcutaneous abdominal fat volume; TAV: total abdominal fat volume; VAV: visceral abdominal
fat volume; VAV%: visceral fat percentage.
In a PLS-DA, differences according to estimated VAV (cm3) and SAV (cm3) below and above the
median were visualized (Figure S2A,B). VIP scores in Figure S2C,D pinpoint the foremost metabolites
which discriminate patients according to values of VAV (cm3) and SAV (cm3) below or above the
median (VIP scores >2.0). Heatmaps of the 50 top-ranked metabolites in patients with (a) VAV (cm3)
and (b) SAV (cm3) values above or below median are shown in Figure 4. These heatmaps indicated
that the subjects were clustered into separate groups according to high and low SAV, compared to VAV.
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Figure 4. Heatmaps of the top metabolites in relation to fat distribution. The most relevant metabolites 
ranked by t-test were used to discriminate a total of 22 patients according to high (red: above median) 
vs. low (green: below median) visceral abdominal fat volume (cm3) (a); and subcutaneous abdominal 
fat volume (cm3) (b). 
Next, all metabolites which were associated with survival (Table 1) and additional metabolites 
associated with abdominal fat distribution (Figure S2 C, D) were included in Spearman’s ranked 
correlation plots, illustrating associations between the selected metabolites and the abdominal fat 
parameters in the subset of patients being examined with CT (Figure S3). Among the strongest 
correlations are the positive associations between creatinine and all CT-parameters in the long 
survival group (rho = 0.648–0.830, p ≤ 0.04), as opposed to no significant associations in the short 
survival group. Moreover, there is a strong correlation between (iso)valerylcarnitine with TAV and 
VAV (rho = 0.830–0.842, p ≤ 0.003) in the long survival group, but not in the short survival group. 
Among patients with short survival, there are significant negative associations for glutamic acid with 
Figure 4. eat a s of the top etabolites in relation to fat distribution. The most relevant metabolites
ranked by t-test ere used to discri inate a total of 22 patients according to high (red: above median)
vs. lo (green: belo edian) visceral abdominal fat volume (cm3) (a); and subcutaneous abdominal
fat volu e (c 3) (b).
ext, all t lit i r ssociated with survival (Table 1) and a ditional metabolites
associate it i al fat distribution (Figure S2C, ) ere included in Spearman’s ranked
correlation plots, illustrating associations between the selected metabolites and the abdominal fat
para eters in the subset of patients being exa ined ith CT (Figure S3). Among the strongest
correlations are the positive associations between creatinine and all CT-parameters in the long survival
group (rho = 0.648–0.830, p ≤ 0.04), as opposed to no significant associations in the short survival
group. Moreover, there is a strong correlation between (iso)valerylcarnitine with TAV and VAV (rho
= 0.830–0.842, p ≤ 0.003) in the long survival group, but not in the short survival group. Among
patients with short survival, there are significant negative associations for glutamic acid with TAV,
Metabolites 2019, 9, 302 8 of 15
VAV, and SAV (rho = −0.580–−0.629, p < 0.05), and also strong negative associations for lysoPC-a-C17:0
with TAV, SAV, and waist circumference (rho = −0.804–−0.741, p ≤ 0.006).
3. Discussion
In the current study, metabolites and metabolic patterns are proposed to be linked with survival
in EC, of which Met SO is standing out as one metabolite of particular interest. Unlike previous
metabolomics studies related to this type of cancer, we aimed to compare groups of patients with
short vs. long survival, despite apparently being matched and similar in other clinical and histological
properties. Moreover, associations between metabolites and abdominal fat distribution were explored.
A strong association of SAV with specific metabolite profiles was observed, whereas no clear associations
could be seen for VAV.
As the most common female cancer, breast cancer has been extensively studied [10–17],
also providing untapped opportunities in metabolomics studies in association with gynecological
cancers. Moreover, biomarkers have been proposed for application in cervical and ovarian cancers
based on metabolomics [18–25].
EC has been less studied in relation to metabolic patterns compared to other gynecological
cancers, but recent studies report interesting associations. Several pathways have been suggested
to be dysregulated in EC, including the lipid metabolism, by comparing cancer tissue samples with
tissue from healthy controls [26]. Moreover, a distinct metabolomic signature of EC has been suggested
by an Italian pilot study using different models [27]. A population-based case-control study also
identified potential biomarkers in relation to EC which were independent of risk factors like obesity
and previously known blood samples, and the authors suggest that metabolic profiling may be
important in its early detection and risk assessment [28]. Moreover, metabolomics have demonstrated
certain metabolites to be associated with histological subtypes [29,30], with recurrence following
surgery [29], and with tumor blood flow in EC patients [31]. A recent study has also evaluated plasma
sphingomyelins and phosphatidylcholines as biomarkers in EC [32], proposing ratios between specific
metabolites as diagnostic and prognostic models. A diagnostic biomarker signature has also been
proposed based on urine metabolomics profiling in EC [33]. A study among subjects with and without
EC showed that the metabolic signature differed from both healthy controls, as well as from benign
endometrial disease and other gynecological cancers [27].
Altogether, there is an increasing interest in metabolomics related to EC, and for the current
study, metabolites involved in amino acid and FA metabolism were mainly investigated. The analyzed
metabolites were part of a high throughput kit assay suitable for the analysis of a large number of
samples and with a superior reproducibility [34]. Moreover, it requires only a small volume of material
for blood analysis. Levels of some metabolites were under the detection limit, which may cause a
bias (indicated in Table 2). Analyses were not adjusted for multiple comparisons, which may be a
limitation. However, we believe that in the current exploratory study, there may be a higher risk in
hiding actual associations due to such adjustments, compared to the risk of revealing false positive
results. It is challenging to use PLS-DA in small datasets, as this method is susceptible to increasing
the chance of creating an overfitted model. Since the current study does not rely exclusively upon the
results from this approach, we believe that PLS-DA is still a useful method for exploring metabolites
which seem to determine cohort differences. Moreover, we have based most signature metabolites on a
VIP score >2, which is conservative compared to most other studies. ROC curves were made based on
several metabolites, and such analysis will provide limited validity in this small study cohort. The
findings of the current study should be verified in a larger patient cohort. In contrast to most studies
where EC cases have been compared to control, we investigated two matched groups of patients with
EC, but with different survival. We did not adjust for potential confounders, which is a limitation.
However, the study design in which patients with long survival were matched with those having
short survival according to several factors including BMI, was arranged in a way which resulted in
adjustment being considered unnecessary. The current findings will thus not necessarily be transferable
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to a typical population-based cohort of patients with EC. Interestingly, a recent publication based on
the same cohort revealed steroid profile as a potential predictor for outcome [6].
Studying properties or activities at the level of genes and proteins has been the most common
way of establishing proposed mechanisms in association with health-related research. However, it is
challenging to adjust for external factors like nutrition, physical activity, or medications when using this
approach. The study of metabolites may be the most promising technique which takes these covariates
into account and presents them as a “summary” of all external inputs [35]. Thus, metabolomics can
be described as the molecular phenotype or biological end points, which culminates in the response
creating the current physiological state, reflecting the other omics, including genomics, transcriptomics,
and proteomics [36]. By using metabolomics, one can investigate a large collection of metabolites,
which contain several promising biomarkers for risk prediction, diagnosis, and even treatment effects,
and end up with certain defined markers related to the outcome of interest, making it very promising
for clinical application [37].
Even though most EC cases are successfully treated by initial surgery, 10–15% of the patients
experience recurrence within five years with an overall poor outcome [38]. Metabolomics as a prognostic
tool may help in identifying patients with an increased risk of recurrence and poor survival, and this
will give an advantage, which would enable health services to follow-up specific patient groups.
The metabolome contains a wide range of small endogenous molecules including, but not limited
to, amino acids, amines, sugars, lipids, nucleic acids, and FAs, as well as methyl-transfer molecules,
each having their own chemical characteristics [39]. Altogether, energy metabolism is affected by
several factors, and an impaired metabolism may lead to disease development or affect its progression,
which may be reflected through several possible metabolic pathways and components.
As mentioned, Met SO did stand out as one important metabolite, elevated in patients with short
survival. Methionine is an essential amino acid and a precursor for succinyl-CoA, homocysteine,
cysteine, creatine, and carnitine [40]. Consequently, this amino acid affects the lipid metabolic
pathway [41], and changes in methionine cycle may be related to adverse health effects. Met SO is
the oxidized form of methionine, and an increased level of this form in the tissues is—under normal
circumstances—related with biological aging [42]. It has been demonstrated that the oxidation of
methionine impairs the reverse transport of cholesterol through apolipoprotein A-I [43]. Furthermore,
a dysfunction in Met SO reductase has been linked with increased cell proliferation, degradation of
extracellular matrix, interfering with key signaling processes, and cancer severity [44].
In proliferating cells, nutrients are transformed into intermediates and then used in the biosynthesis
of FAs, cholesterol, sugar derivatives like hexose, glycerol, nucleotides, and non-essential amino
acids [45]. Important intermediates include one-carbon metabolites, S-adenosylmethionine (SAM),
and several metabolites which are involved in glycolysis and the TCA cycle. SAM is a methyldonor
involved in epigenetic changes in gene expression, which is generated from the transmethylation
pathway from the metabolism of methionine [46]. Moreover, SAM is involved in the synthesis of
phosphatidylcholine. The observed higher circulating levels of Met SO in patients with short—compared
with long—survival, may reflect a decrease in metabolism through the transmethylation cycle in such
patients, and may thus be a potential underlying mechanism causing an impaired cellular function.
Interestingly, retinol metabolism was identified as being significantly associated with survival based
on the joint pathway analysis. DNA methylation of genes in relation to retinoid signaling is linked to
carcinogenesis in several cancers, including EC [47]. Moreover, retinoic acid activates the peroxisome
proliferator activated receptor delta, which is central to FA metabolism [48]. Such activation induces
oxidative metabolism so that glycolysis is reduced [49].
Hypoxic conditions in tumors lead to a deficiency in the de novo production of unsaturated FAs
due to the impaired stearoyl-CoA desaturase 1 induction of double bonds. Instead, unsaturated FAs
formed as lysophospholipids are recruited from the surroundings [50]. It has also been demonstrated
that metastatic ovarian cancer cells may import FAs from the adipocytes through the upregulation
of FABP4 [51]. Overall, tumorigenesis promotes de novo lipid production which leads to changes
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in membrane composition towards oxidized saturated FAs—an adaptation to oxidative stress [52].
Furthermore, the upregulation of major enzymes involved in biosynthesis of fatty acyl chains is
associated with transformed cells [4]. Reactive oxygen species (ROS) may be excessively generated in
proliferating cells due to accumulated electron transport flux, and can activate transcription factors
like HIF1α and NRF2 making further contributions to tumorigenesis [4].
Previous work by our group has demonstrated a high VAV percentage to be associated with
adverse outcomes in patients with EC [5]. Based on these findings we performed a subgroup analysis
including on those in the current study who also had CT data available. Interestingly, a defined pattern
appears to be present when stratifying the cohort into extents of VAV and SAV, respectively, with a
particularly well-defined pattern for SAV. Notably, abdominal subcutaneous adipose tissue has been
demonstrated to increase in women up till 60–70 years, and is overall more insensitive to weight
reduction compared to visceral fat [53]. Several metabolites correlate with SAV, which seems to predict
prognosis to a lesser extent than VAV, being compliant with the weak associations between metabolites
and survival. The data on abdominal fat distribution, as measured by CT, adds interesting perspectives
to the current study, although the number of included patients is low.
Overall, being a small study cohort, the findings would not necessarily be reflected in a similar
larger cohort or at the population level. However, we believe that the current study illustrates that
metabolomics is a promising future approach when exploring potential biomarkers for clinical use.
4. Materials and Methods
4.1. Study Population
All samples were retrieved from The Bergen Gynecologic cancer biobank (REK 2014/1907).
The biobank includes samples prospectively collected from patients diagnosed with gynecological
cancer in Western Norway between 2001 and 2015 and is a population-based patient series. Included
patients gave written informed consent. The biobank has been thoroughly described previously [54].
A subgroup of 20 patients with short survival time and having either FIGO (International Federation
of Gynecology and Obstetrics 2009 criteria) stage 1 and grade 1–3, or having stage 2 and grade 2
diseases were selected from this cohort. From the same cohort, 20 patients with long survival were
matched with those having short survival for FIGO stage, histology, grade, age, body mass index
(BMI), and parity, and were selected for the analyses.
The study was performed in accordance with the principles of the Declaration of Helsinki and
was approved by the Regional Committee for Medical Research Ethics (REK 2009/2315).
4.2. Metabolomic Profiling
EDTA blood was obtained before primary surgery. The samples were centrifuged at 1600× g for
15 min and the plasma was stored at −80 ◦C until analysis was performed. Non-fasting plasma samples
were analyzed on a multiplex platform which included 183 metabolites (Biocrates: AbsoluteIDQ®
p180 kit assay, Innsbruck, Austria). The complete metabolomics data were produced at the contract
research department of Biocrates (Innsbruck, Austria) according to the company protocol [55]. In short,
the samples were cleared by centrifugation and then analyzed. The automated assay was based on
PITC (phenylisothiocyanate)-derivatization in the presence of internal standards. For the quantification
of acylcarnitines, lipids, and hexose, flow-injection-analysis (FIA)-MS/MS was used, where 20 µL of
sample was directly injected into the mass spectrometer via electrospray ionization using an AB SCIEX
4000 OTrap® mass spectrometer (AB SCIEX, Darmstadt, Germany). Amino acids and biogenic amines
were analyzed by LC/MS. The samples (10 µL) were injected on a reverse-phase column and the column
eluent was introduced directly into the mass spectrometer by electrospray ionization and using an
AB SCIEX 4000 OTrap® mass spectrometer (AB SCIEX, Darmstadt, Germany). For each metabolite,
the limit of detection (LOD) was calculated as three-times the median of the concentrations in the zero
sample for the metabolite under consideration.
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4.3. Transcriptomics
RNA was extracted from primary tumor tissue using the RNeasy Mini Kit (Qiagen, Germantown,
MD, USA). Microarrays [5,56] and RNA-sequencing were performed as previously described [6].
4.4. Image Analysis on CT Scans
Diagnostic abdominal preoperative CT scans were performed as routine diagnostic procedures
and were available in 22 patients. An assessment of abdominal fat was performed by a semi-automated
method for volumetric quantification (iNtuition, TeraRecon Inc., San Mateo, CA, USA) [57], from which
the visceral (VAV) and subcutaneous (SAV) abdominal fat volumes were estimated (cm3). The total
abdominal fat volume (TAV) was then considered as the sum of VAV and SAV. Percentage of visceral
abdominal fat volume (VAV%) was then calculated ([VAV/TAV] × 100; VAV%). Waist circumference
was measured in an axial image at the L3/L4 level (iNtuition, TeraRecon Inc., San Mateo, CA, USA).
4.5. Statistical Analyses
Medians (25th, 75th) and counts (%) were reported for the continuous and categorical variables,
and differences between groups were calculated using the Mann–Whitney U test for continuous
variables and Chi-square for independence on binary variables.
Log-transformed data were imported into the MetaboAnalyst 4.0 software (Xia Lab, McGill
University), in which t-tests were performed for metabolite levels between specified groups and fold
change was detected. PLS-DA was used to detect variable importance in projection (VIP) scores.
Metabolites which significantly differed as calculated by the Mann–Whitney U test, which had a fold
change threshold of 2, and/or a VIP value >2.0, were selected for the proposed metabolic signature
according to survival. Moreover, heatmaps were generated by hierarchical clustering using the
Euclidean distance measure and the Ward algorithm, based on the top 50 metabolites which differed
most according to the group in question.
We explored model discrimination by calculating areas under receiver operator characteristics
curves (ROC–AUC) on both separate components, as well as on metabolic signatures. For subgroup
analysis, Spearman-ranked correlation was used to illustrate the association between selected
metabolites and abdominal fat distribution parameters. Furthermore, the 22 patients with available
preoperative CT data were stratified according to high vs. low VAV and SAV, as defined by each of
their median [5].
Statistical analyses were performed using IBM SPSS Statistics for Windows, version 24 (SPSS,
Armonk, NY, USA), R version 3.2.5 (R Development Core Team, Vienna, Austria), and MetaboAnalyst
4.0 [58]. Probability values were two-sided and considered statistically significant when p < 0.05.
5. Conclusions
This study revealed that metabolic signatures are associated with survival and abdominal fat
distribution in EC. Thus, metabolomic profiling stands out as a robust approach in prognostic
assessment. In the future, metabolomics profiling may serve as a useful tool for identifying targets in
treatment as well as patient groups in need of close follow-up.
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